tirzepatide trial obesity without diabetes surmount-1 for Obesity: Highlights from the going from 2.5 to 5 – Breaking: Lilly's Zepbound® (tirzepatide) outperforms

Mnogo sam manje agresivan, mnogo manje elim da se svaam, mnogo sam mirniji i priljiviji

Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: the SURFASA score

Women are looking for: Sustainable weight loss rather than rapid drops Programs that account for hormones and fatigue Predictable monthly costs Support beyond just medication At the same time, access challenges and rising costs of brand-name options have pushed many to explore compounded GLP-1 programs as a long-term solution rather than a temporary fix

Pfizer has positioned berobenatide as the first monthly GLP-1 likely to seek approval